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Objective To assess trends in the susceptibility to b-lactam agents and to ﬂuoroquino-
lones of clinically relevant Enterobacteriaceae isolated over a 3-year period in 14 French
hospital laboratories.
Methods During the second quarter of 1996, 1997 and 1998, 180 consecutive non-
duplicate isolates of Enterobacteriaceae were collected in each center. Sixteen b-lactams
and four quinolones were tested by the disk diffusion method. In addition, the double-
disk synergy test was used to screen for the production of extended-spectrum b-
lactamase (ESBL).
Results Totals of 2507, 2312 and 2506 clinical isolates were obtained in each period,
respectively. The distribution of Enterobacteriaceae species according to clinical specimens
and wards was similar in each study period. No signiﬁcant variation in the susceptibility
rates to b-lactams and ﬂuoroquinolones was observed, except in Klebsiella pneumoniae and
Enterobacter aerogenes. The prevalence of ESBL-producing isolates decreased from 18% to
9% in the former, while it increased from 32% to 54% in the latter. At the same time, the
susceptibility to oﬂoxacin and peﬂoxacin increased for K. pneumoniae (P< 0.003) and
cephalosporinase-producing species (P< 0.05), except Enterobacter spp.
Conclusion Over the 3-year study period b-lactams and ﬂuoroquinolones remained
highly active against Enterobacteriaceae clinical isolates, with the exception of E. aerogenes,
probably as a result of the dissemination of multiresistant clones in French hospitals.
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INTRODUCTION
In France, b-lactam agents and ﬂuoroquinolones
are the antibiotics most frequently prescribed for
treating Enterobacteriaceae infections. The clinical
importance of Enterobacteriaceae with the potential
to acquire resistance to b-lactams related to inhi-
bitor-resistant b-lactamases, extended-spectrum
b-lactamases (ESBLs) or stably derepressed cepha-
losporinases was demonstrated by previous resis-
tance surveys in France [1–4]. Resistance to
ﬂuoroquinolones has recently been shown to be
increasing among Enterobacteriaceae in Europe,
particularly in Spain [5–7]. This multicenter study
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was carried out in 14 French hospital laboratories
during a 3-year period, in order to assess the in
vitro susceptibility of clinically relevant Entero-
bacteriaceae isolates to b-lactam agents and to
ﬂuoroquinolones.
MATERIALS AND METHODS
Participating centers
The survey was conducted in 14 French hospitals,
seven of 29 metropolitan university hospitals and
seven non-teaching hospitals, in 11 different
regions, including Ile-de-France (Paris region).
Clinical isolates
During the second quarter of 1996, 1997 and 1998,
the participating hospital laboratories each col-
lected the ﬁrst 180 non-duplicate isolates obtained
from clinically signiﬁcant specimens, according to
the reference procedures from the French Society
of Microbiology [8]. Isolates from superﬁcial
wounds, from ear, nose and throat and from swab
samples were excluded.
Susceptibility testing
The disk diffusion method on Mueller–Hinton
agar (Sanoﬁ Diagnostics Pasteur, Marnes-la-
Coquette, France) was performed in each center
according to the recommendations of the Antibio-
gram Committee of the French Society for Micro-
biology [9]. ESBLs were detected by the double-
disk synergy test, demonstrating a synergistic
effect between co-amoxiclav or ticarcillinþ clavu-
lanic acid and either cefotaxime, ceftazidime or
aztreonam [10]. Cefpirome and cefepimewere also
used to detect ESBLs among cephalosporinase-
hyperproducing isolates, as previously described
[11]. Escherichia coli ATCC 25922 and Escherichia
coli C600/pCFF04 (TEM-3) were used as quality
controls once a week.
Twenty antibiotics were tested (the zone dia-
meter breakpoints in mm are indicated in paren-
theses): amoxicillin (21–14), co-amoxiclav (21–14),
ticarcillin (22–18), ticarcillinþ clavulanic acid (22–
18), piperacillin (20–12), piperacillinþ tazobactam
(21–14),cephalothin(18–12), cefoxitin (22–15),mox-
alactam (23–17), cefotaxime (21–15), ceftazidime
(21–15), aztreonam (23–17), cefpirome (21–15),
cefepime (21–15), cefpodoxime (24–21), imipenem
(22–17), nalidixic acid (20–15), oﬂoxacin (22–16),
peﬂoxacin (22–16) and ciproﬂoxacin (22–19). Bac-
terial strains were classiﬁed as susceptible, inter-
mediate and resistant. Isolates showing a positive
double-disk synergy test were classiﬁed as non-
susceptible to all third-generation cephalosporins
and aztreonam, whatever the size of the inhibition
zone diameter.
Statistical analysis
The variation in the susceptibility rate over the
3-year period was analyzed by asymptotic chi-
square test for trend or by an exact trend test
when the number of resistant isolates was parti-
cularly small. Regarding the risk of false-positive
results due to multiple statistic tests, it can be
assumed, from Benjamini et al. [12], that the
nominal alpha risk of 0.05 to deﬁne signiﬁcant
differences would lead in this analysis to a high
risk of false-positive results (1/3), whereas the
P-value of 0.003 would provide a lower risk of
false positivity (1/8). Nevertheless, tests with
P-values between 0.003 and 0.05 will be presented
in the results.
RESULTS
Distribution of clinical isolates
Of the 7325 isolates collected during the 3-year
study period, 88.9% were from adult wards and
10.1% from pediatric wards (data not available in
1%). In total, 6248 (85.3%) isolates were obtained
from patients hospitalized in a medical ward
(43.1%), surgical ward (19.8%), intensive care units
(ICUs) (13.3%) and geriatrics ward (10.4%), and
1049 (14.3%) from emergency wards and outpati-
ents (0.4% not available). Among the 7325 isolates,
70%were recovered fromurine, 7.8% from respira-
tory tract samples, 8.1% from blood, 10.6% from
abscesses and drainage ﬂuids, and 3.4% from other
clinical specimens.
The overall distribution of bacterial species was
as follows: Escherichia coli 63.4%, Proteus mirabilis
8.4%, Klebsiella pneumoniae 5.9%, Morganella,
Providencia and indole-positive Proteus 4.2%,
Enterobacter cloacae 3.9%, Klebsiella oxytoca (3.1%),
Enterobacter aerogenes 3.0%, Serratia marcescens
2.2%, Salmonella spp. 1.5%, Citrobacter freundii 1.2%
and Citrobacter diversus 1.0%. This distribution was
similar in each study period. E. coli constituted
80.3% of the isolates in emergency wards and
outpatients, but only 43.9% in ICUs, in which
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the proportions of Enterobacter spp. (14.4%) and
Klebsiella spp. (13.4%) were higher than in other
wards. E. coli was the most frequent Enterobacter-
iaceae isolate in urine (72.3%), blood (68.9%),
abscesses (48.3%) and respiratory tract samples
(24.6%). P. mirabilis was the second most common
isolate (8.4%) encountered in clinical specimens,
more often from respiratory tract (11.5%),
abscesses (9.9%) and urine (8.4%), and more often
in geriatric wards (13.9%) than in other wards.
Cephalosporinase-producing species, including
Enterobacter spp., Serratia spp., indole-positive Pro-
teus, Morganella spp. and Providencia spp., repre-
sented 30.7% of the isolates in ICUs. This bacterial
group represented 46.6% of the isolates from
respiratory tract samples and 29.2% of those from
abscesses and serous effusions.
In vitro susceptibility to antibiotics
The susceptibility of the Enterobacteriaceae isolates
to b-lactams and to ﬂuoroquinolones in 1998 is
shown in Table 1 and Table 2.
For all Enterobacteriaceae isolates, imipenem,
extended-spectrum cephalosporins and aztreo-
nam were the most active b-lactam agents, follow-
ed by piperacillinþ tazobactam. Fluoroquinolones
exhibited good in vitro activity, except for E. aero-
genes and Providencia stuartii isolates, for which the
susceptibility rates were less than 50%.
The susceptibility rates of the predominant spe-
cies, Escherichia coli, to amoxicillin, co-amoxiclav,
cefotaxime, nalidixic acid, oﬂoxacin and ciproﬂox-
acin, according to clinical specimens and wards,
are shown in Table 3.
Although no signiﬁcant change was observed in
the susceptibility rates to b-lactams and quinolo-
nes among the Enterobacteriaceae overall, species-
to-species analysis revealed individual variation
during the 3-year study period.
For E. coli, susceptibility to cephalothin increa-
sed from 62.9% to 68.7% (P< 0.001). Among quino-
lones, the susceptibility of E. coli isolates to
ciproﬂoxacin seemed to decrease (P¼ 0.04) from
97.2% to 95%.
For P. mirabilis isolates, a slight decrease in
susceptibility (P 0.05) to cefotaxime (P¼ 0.03)
and aztreonam (P¼ 0.04) was observed.
For K. pneumoniae, we observed a >8% increase
of the susceptibility rate to extended-spectrum
cephalosporins and to aztreonam (P 0.05),
and, at the same time, a signiﬁcant decrease T
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(P¼ 0.04) in ESBL-producing isolates (Table 4).
The susceptibility of K. pneumoniae isolates to
peﬂoxacin (66% versus 81.9%), oﬂoxacin (68.7%
versus 84.1%), nalidixic acid (65.3% versus 76.8%,
P¼ 0.03) and ciproﬂoxacin (80.3% versus 88.4%)
increased.
For cephalosporinase-producing species, the
susceptibility to ticarcillin (51.3–58.9%, P¼ 0.04)
and to quinolones (nalidixic acid, peﬂoxacin
and oﬂoxacin, P¼ 0.01–0.04) increased. ESBL-pro-
ducing isolates increased by more than 20%
(P¼ 0.01) over the 3-year period in E. aerogenes
(Table 4).
The distribution of ESBL-producing K. pneu-
moniae and E. aerogenes isolates according to
specimens and wards is shown in Table 5.
These isolates were recovered mainly from urine,
Table 2 Susceptibility (%) of Enterobacteriaceae isolates to
quinolones in 1998
Species (n) NAL PEF OFX CIP
Escherichia coli (1606) 89.7 91.2 93.6 95.8
Proteus mirabilis (215) 74.0 80.0 80.5 85.1
Salmonella spp. (32) 90.6 93.8 100.0 100.0
Klebsiella pneumoniae (138) 76.8 81.9 84.1 88.4
Klebsiella oxytoca (81) 84.0 85.2 88.9 91.4
Citrobacter diversus (30) 76.7 80.0 80.0 83.3
Enterobacter cloacae (109) 77.1 79.8 83.5 86.2
Enterobacter aerogenes (86) 30.2 33.7 36.1 37.2
Citrobacter freundii (32) 65.6 68.8 75.0 78.1
Serratia marcescens (49) 61.2 61.2 61.2 71.4
Morganella morganii (67) 86.6 86.6 86.6 89.6
Providencia stuartii (15) 33.3 33.3 33.3 53.3
Proteus vulgaris (25) 100.0 100.0 100.0 100.0
NAL, nalidixic acid; PEF, pefloxacin; OFX, ofloxacin; CIP,
ciprofloxacin.
Table 3 Susceptibility (%) of E. coli isolates to b-lactam agents and quinolones in 1998, according to clinical specimens and
wards
n AMX AMC CTX NAL OFX CIP
Specimens
Urine 1213 55.8 78 99.6 89.6 93.3 95.6
Respiratory tract 46 43.5 58.7 100.0 89.1 89.1 91.3
Blood 148 58.1 78.4 98.7 90.5 96.0 97.3
Abscesses and drainage fluids 166 47.0 72.3 98.8 89.8 94.6 96.4
Emergency wards and outpatients 295 59.0 80.0 99.3 94.2 96.3 97.6
Inpatients (total)a 1311a 53.7 75.9 99.4 88.7 93.0 95.4
Medicine 577 58.1 78.5 99.7 89.3 93.2 95.7
Surgery 243 50.2 71.6 99.6 88.9 93.8 96.3
Intensive care units 120 56.7 74.2 98.3 89.2 93.3 95.8
Geriatrics 143 53.2 74.1 99.3 78.3 83.9 88.8
AMX, amoxicillin; AMC, co-amoxiclav; CTX, cefotaxime; NAL, nalidixic acid; OFX, ofloxacin; CIP, ciprofloxacin.
aTwo hundred and twenty-eight isolates were from various wards.
no. of ESBLþ/no. of isolates (%)
Species 1996 1997 1998
Escherichia coli 2/1620 (0.12) 2/1483 (0.13) 8/1606 (0.5)
Proteus mirabilis 4/209 (1.9) 4/194 (2.1) 11/215 (5.1)
Klebsiella pneumoniae 26/147 (17.7) 21/149 (14) 13/138 (9.4)
Enterobacter aerogenes 21/66 (31.8) 38/68 (55.9) 46/86 (53.5)
Enterobacter cloacae 1/89 (1.1) 5/85 (5.9) 3/109 (2.8)
Citrobacter freundii 0/23 2/32 (6.3) 0/32
Providencia stuartii 4/21 (19) 0/16 0/15
Serratia marcescens 0/72 1/40 (2.5) 0/49
Salmonella spp. 1/41 (2.4) 0/39 1/11 (9.1)
Table 4 Frequency of ESBL-produ-
cing Enterobacteriaceae isolates over
the 3-year period
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respiratory tract specimens, abscesses or serous
effusions. The proportion of ESBL-producing
strains among the E. aerogenes isolates was similar
in medical units, surgical units, ICUs and geriatric
wards.
DISCUSSION
The data collected in the microbiological labora-
tories of 14 hospitals during this 3-year survey
update the distribution and the susceptibility pat-
tern to b-lactams and quinolones of Enterobacter-
iaceae isolates responsible for infections in French
hospitals.
It should be noted that one isolate of the same
species per patient was considered as a non-dupli-
cate strain instead of one per specimen, as recom-
mended by the ONERBA (Observatoire National
de l’Epide´miologie de la Re´sistance aux Antibio-
tiques) [13]. Thus, some isolates are missing in the
sub-analysis of the results according to clinical
specimens. However, this did not signiﬁcantly
alter the results, since the total number of isolates
was large.
E. coli represented 64.3% of the total isolates and,
as in previous studies, it was the predominant
pathogen in urine samples [1,2,14].
Cefotaxime, ceftazidime, cefpirome, cefepime,
aztreonam and imipenem had the best overall
activity among the b-lactams tested against Enter-
obacteriaceae.
During the 3-year period, the overall rate of
susceptibility to b-lactam agents and ﬂuoroquino-
lones remained unchanged. However, some var-
iations in the percentage of susceptible strains
were observed at the species level.
More than 99% of E. coli isolates remain suscep-
tible to cefotaxime. The frequency of E. coli isolates
producing an ESBL was 0.12–0.5%, while the cef-
tazidime resistance rate was 1.2–1.6%. This dis-
crepancy can be related to isolates overproducing
a cephalosporinase, as conﬁrmed by the 1% of E.
coli isolates with full resistance to cefoxitin (data
not shown).
This high rate of susceptibility Escherichia coli to
third-generation cephalosporins and aztreonam
contrasted with the 76.7% susceptibility to co-
amoxiclav. This is in accordance with other
multicenter studies conducted in France between
1988 and 1993 [1,2,15,16]. However, the co-
amoxiclav susceptibility among E. coli isolates
was reported to be variable in French hospitals
from different regions [14,17,18]. In our study,
the lowest frequency of co-amoxiclav-susceptible
E. coli (58.7%) was observed in respiratory tract
samples.
The rates of susceptibility to ﬂuoroquinolones
of Escherichia coli isolates were 96.6%, 94% and
91.3% to ciproﬂoxacin, oﬂoxacin and peﬂoxacin,
respectively, as described by other authors [18].
Nevertheless, a slight decrease (1.4%, P¼ 0.04) in
susceptibility to ciproﬂoxacin was noted.
Six per cent of the total Enterobacteriaceae isolates
were intermediate or resistant to cefotaxime, cor-
responding to isolates producing a chromosomal
cephalosporinase and to those producing an ESBL.
Table 5 Distribution of ESBL-producing K. pneumoniae and E. aerogenes isolates according to specimens and wards
no. of ESBLþ/no. of isolates
Klebsiella pneumoniae Enterobacter aerogenes
1996 1997 1998 1996 1997 1998
Specimens/Wards 26/147
(17.7%)
21/149
(14.1%)
13/138
(9.4%)
21/66
(37.8%)
38/68
(55.9%)
46/86
(53.5%)
Urine 15/108 15/103 7/90 8/32 24/41 28/41
Respiratory tract 4/13 1/18 4/18 4/11 9/16 7/20
Blood 1/10 1/10 0/15 1/7 0/1 4/7
Abscess and drainage fluids 6/14 4/17 2/13 8/15 3/8 4/11
Others 0/2 0/1 0/2 0/1 2/2 3/7
Emergency wards and outpatients 0/6 0/7 1/10 2/5 1/3 1/4
Medicine 6/63 12/60 3/58 13/35 13/22 20/36
Surgery 8/25 5/25 3/26 1/11 3/11 11/22
Intensive care units 8/24 2/20 4/19 3/13 11/18 10/18
Geriatrics 2/20 1/20 2/16 1/1 4/6 3/5
Others 2/9 1/17 0/9 0/1 6/8 1/1
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Ten years after the study of Sirot et al. [1], this
incidence increased from 5.2% to 6%.
Comparing these results with those of other
studies conducted in Europe is difﬁcult because
of methodological differences in susceptibility
testing and breakpoint criteria. However, previous
reports devoted to antibiotic resistance in Gram-
negative bacilli have shown similar activity of b-
lactam agents against Enterobacteriaceae [19,20].
One of the most important trends revealed by
this study is the increasing susceptibility of K.
pneumoniae to third-generation cephalosporins
and aztreonam, related to the decrease of ESBL-
producing isolates, probably as a consequence of
epidemic control measures instituted in hospitals
[21]. Thabaut et al. [15], in a multicenter study
including 17 hospitals, noted that the frequency of
K. pneumoniae strains resistant to ceftazidime and
cefotaxime, after peaking at 24% in 1991, fell to
18% in 1993. In our study, the percentage of K.
pneumoniae isolates producing an ESBL decreased
from 17.7% to 9.4%. Conversely, European surveys
in ICUs in 1994 and in 1997–98 demonstrated that
the prevalence of ESBL among Klebsiellawas about
25% and remained unchanged [22,23].
At the same time, an increase of susceptibility to
ﬂuoroquinolones was observed in K. pneumoniae,
particularly to oﬂoxacin and peﬂoxacin. Contrary
to the results published by Brisse et al. [24], we
observed that the increase in susceptibility to
ﬂuoroquinolones was linked to the increase in
susceptibility to third-generation cephalosporins.
Another outstanding feature is the >20%
increase in ESBL-producing strains of E. aerogenes,
leading to a dramatic decrease in susceptibility
rates (<50%) to third-generation cephalosporins
and aztreonam. As shown by Bosi et al. [25], this
can be explained by the spread in French hospitals
of ESBL-producing strains of E. aerogenes belong-
ing to a prevalent clone.
For K. oxytoca, a positive double-disk synergy
test may indicate an ESBL or overproduced chro-
mosomal OXY-type b-lactamase [11]. Thus, sus-
ceptibility to third-generation cephalosporins may
have been underestimated, since these isolates
were never considered as susceptible to these
antibiotics [9]. In our study, ESBLs were found
in only three isolates of K. oxytoca (data not
shown). Without any interpretation, the overall
rate of susceptibility over the 3 years was 96% to
cefotaxime, 97% to ceftazidime, 94.6% to cefpir-
ome, 98% to cefepime and 83% to aztreonam.
In conclusion, after many years of use in French
hospitals, third-generation cephalosporins and
ﬂuoroquinolones retain good in vitro activity
against the most frequent isolates of the family
Enterobacteriaceae, except E. aerogenes. Further stu-
dies are needed to understand why this species is
currently the predominant ESBL-producing Enter-
obacteriaceae species in France.
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